Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VOICE-Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease Using Patient-Reported Outcome Measures: A Prospective Observational Study

NCT06249555 is registered in ClinicalTrials.gov with Alimentiv Inc. as lead sponsor.

NCT NCT06249555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06249555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VOICE-Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease Using Patient-Reported Outcome Measures: A Prospective Observational Study
Lead sponsor
Alimentiv Inc.
Phase
Observational
Overall status
Active, not recruiting
Start date
March 20, 2024
Completion date
December 31, 2026
Enrollment
300 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease